The study demonstrated that circulating tumor DNA (ctDNA) methylation analysis is a valuable prognostic tool for long-term outcomes in stage IV colorectal cancer. Patients with high levels of CHFR-rmv experienced significantly worse recurrence-free survival compared to those with low levels (p = 0.001), establishing CHFR-rmv as an independent prognostic factor (hazard ratio = 2.63). Likewise, high SOX11-rmv levels indicated poorer outcomes post-surgery (p = 0.004). These findings advocate for future investigations in this area.
• Why it matters: y
Journal Article by Momose H, Sugimoto K (…) Sakamoto K et 6 al. in J Surg Oncol
© 2024 Wiley Periodicals LLC.